Truveta
From AltData.wiki, The Alternative Data Encyclopedia
Truveta is an American health data and analytics company headquartered in Bellevue, Washington, owned and governed by a collective of United States health systems.[2] The company aggregates de-identified electronic health records, claims, images, genomics, and other clinical data into a daily-updated dataset covering more than 130 million patients, which it delivers through analytics platforms and evidence services for life sciences, healthcare, and public health customers.[1][2][5].
Founded in 2020 by Providence, Advocate Health, Tenet Healthcare, and Trinity Health, Truveta was publicly introduced in February 2021 with fourteen founding health system members and has since grown to roughly thirty member systems.[2][4] Former Microsoft executive Terry Myerson serves as chief executive officer.[2]
What It Does
Truveta links longitudinal patient records across its member health systems, harmonizing structured and unstructured data so that researchers can study real-world care as it happens. The company describes its mission as turning yesterday's care into today's intelligence, supporting use cases from drug discovery and safety surveillance to clinical trial simulation and care benchmarking.[1]
Its work is organized around three offerings: Truveta Data, the underlying linked dataset; Truveta Intelligence, an analytics product that answers research questions in minutes; and Truveta Evidence, comprising a trusted research environment and expert services that produce audit-ready studies aligned to regulatory standards.[1]
Data and Methodology
Truveta Data combines electronic health records, closed claims, device data, medical images, social determinants of health, mother-child linkages, multiomics, and mortality data, updated daily rather than through periodic releases. Clinical notes are structured using the Truveta Language Model, a multimodal large language model introduced in 2023 to extract meaning from unstructured clinician documentation.[1][2]
In 2025 the company launched the Truveta Genome Project in collaboration with participating health systems, Regeneron, Illumina, and Microsoft, aiming to genotype millions of health system patients; the effort was announced alongside a US$320 million Series C funding round.[3]
Research outputs are extensive: the company cites more than 350 publications, over 250 conference presentations, more than 150,000 citations of its data, and upwards of 100 regulatory projects across United States and global agencies. Studies using Truveta data have appeared in journals including JAMA Network Open, JAMA Internal Medicine, JAMA Pediatrics, Vaccine, and JACC: Heart Failure, covering topics such as GLP-1 receptor agonist persistence, semaglutide versus tirzepatide effectiveness, COVID-19 breakthrough infections, and pediatric speech delay trends.[1][2]
Products
- Truveta Data — the complete, real-time linked dataset spanning EHR, claims, devices, images, SDOH, mother-child links, multiomics, and mortality.[1]
- Truveta Intelligence — an interface where users ask questions and receive answers with verifiable methodology behind each result.[1]
- Trusted Research Environment — immediate access to Truveta Data with reusable, clinically precise cohort definitions and audit-ready output aligned to regulatory standards.[1]
- Evidence Services — expert-led study design and execution extending customer capacity from protocol to submission.[1]
Delivery and Pricing
Customers access platforms through cloud subscriptions, including sign-in via studio.truveta.com, with enterprise agreements scoped by data domains, therapeutic areas, and service levels. Pricing is not published publicly.[1]
The company was built with and remains owned by United States health systems, which differentiates its governance model: member systems both supply data and hold equity, while commercial subscriptions fund the platform.[1][2]
Buyers and Use Cases
Customers include pharmaceutical companies such as Pfizer, the company's first life sciences customer in 2022, and Moderna and Boehringer Ingelheim; medical device makers such as Boston Scientific; healthcare provider organizations; academic researchers; and public health agencies.[1][2]
Use cases span discovery and AI training, therapy adoption tracking such as real-time monitoring of GLP-1 market share, safety signal detection trusted by regulators, outcomes research, clinical trial simulation and patient identification, and healthcare operations benchmarking. The company's research arm has published widely covered analyses on topics including cyclosporiasis outbreaks, oral obesity medication uptake, and e-bike injury trends.[1]
History
Truveta was formed in September 2020 by a group of United States health systems seeking a shared data resource, spearheaded by Providence, Advocate Health, Tenet Healthcare, and Trinity Health, and was publicly introduced in February 2021 with fourteen founding members including CommonSpirit Health, Northwell Health, Henry Ford Health System, and Memorial Hermann.[2][4]
In 2021 the company entered a cloud and artificial intelligence partnership with Microsoft that included a strategic investment, and later that year released its first data platform after raising close to US$200 million.[2] Pfizer became its first life sciences customer in June 2022, initially collaborating on monitoring COVID-19 vaccines and therapies, and Boston Scientific began using the platform the same year.[2]
The Truveta Language Model launched in April 2023 to structure clinical notes at scale.[2] In January 2025 the company announced the Truveta Genome Project with Regeneron and Illumina alongside US$320 million in Series C funding, reporting participation from thirty health systems and an increased genomic sequencing goal.[2][3]